NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
29 hedge funds and large institutions have $991K invested in NeuBase Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
5% less capital invested
Capital invested by funds: $1.05M → $991K (-$55K)
12% less funds holding
Funds holding: 33 → 29 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43.6K |
| 2 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
+$11.9K |
| 3 |
VF
Virtu Financial
New York
|
+$11.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.56K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$2.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$11K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.57K |
| 4 |
GBA
Garrison Bradford & Associates
New York
|
-$7.91K |
| 5 |
FNBT
FineMark National Bank & Trust
Fort Myers,
Florida
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FNBT
26
FineMark National Bank & Trust
Fort Myers,
Florida
| – | -$4K | -56 | Closed |
|
27
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$2K | -26 | Closed |
|
28
State Street
Boston,
Massachusetts
| – | -$2K | -26 | Closed |
|
29
JP Morgan Chase
New York
| – | -$1K | -7 | Closed |
|
|
AA
30
Ancora Advisors
Cleveland,
Ohio
| – | +$377 | +5 | New |
|
NBSE Hedge Fund Activity: Q3 2018 in Review
29 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2018, worth a combined $991K — down 5.3% from $1.05M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NBSE and 3 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $43.6K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $33K sold.
- 29 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2018, down from 33 in Q2 2018.
- Funds reported $991K of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2018, down 5.3% quarter-over-quarter.
- 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2018 and 7 closed out, a net change of -4 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2018 was Renaissance Technologies, an estimated $43.6K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2018 was Susquehanna International Group, an estimated $33K sold.
Based on aggregated 13F filings for Q3 2018.